Folegatti, Pedro M. http://orcid.org/0000-0001-5330-0240
Harrison, Kate http://orcid.org/0000-0002-2419-4415
Preciado-Llanes, Lorena http://orcid.org/0000-0001-5120-3578
Lopez, Fernando Ramos http://orcid.org/0000-0002-9997-7879
Bittaye, Mustapha
Kim, Young Chan http://orcid.org/0000-0003-2847-9407
Flaxman, Amy http://orcid.org/0000-0001-6460-1372
Bellamy, Duncan http://orcid.org/0000-0003-3614-0032
Makinson, Rebecca
Sheridan, Jonathan http://orcid.org/0000-0002-6806-2609
Azar, Sasha R. http://orcid.org/0000-0002-9182-216X
Campos, Rafael Kroon http://orcid.org/0000-0002-4852-0449
Tilley, Mark
Tran, Nguyen
Jenkin, Daniel
Poulton, Ian http://orcid.org/0000-0002-6603-8461
Lawrie, Alison
Roberts, Rachel
Berrie, Eleanor
Rossi, Shannan L.
Hill, Adrian http://orcid.org/0000-0003-0900-9629
Ewer, Katie J. http://orcid.org/0000-0001-9827-9836
Reyes-Sandoval, Arturo http://orcid.org/0000-0002-2648-1696
Funding for this research was provided by:
Innovate UK (971557)
Article History
Received: 9 February 2021
Accepted: 12 July 2021
First Online: 30 July 2021
Competing interests
: Pedro M. Folegatti is a consultant to Vaccitech, which is developing adenoviral vectored vaccines. Adrian Hill is a cofounder of and consultant to Vaccitech Ltd and is named as an inventor on a patent covering the design and use of Ch.